ARAY:NSD-Accuray Incorporated (USD)

COMMON STOCK | Medical Devices | NSD

Last Closing Price

USD 4.31

Change

+0.26 (+6.42)%

Market Cap

USD 0.37B

Volume

0.58M

Average Target Price

USD 8.00 (+85.61%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Accuray Incorporated designs, develops, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body in the Americas, Europe, the Middle East, India, Japan, Africa, and rest of the Asia Pacific region. The company offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body. Its CyberKnife System automatically tracks, detects, and corrects for tumor and patient movement in real-time during the procedure, as well as enables the delivery of precise, high dose radiation while patients breathe normally. The company also offers the TomoTherapy System, including the Radixact System, which consists of an integrated and versatile radiation therapy system used for the treatment of a range of cancer types. It markets its products in the United States directly, as well as through sales organizations, sales agents, and group purchasing organizations; and directly, as well as through distributors and sales agents in Europe, Asia, and South America to hospitals and stand-alone treatment facilities. The company was incorporated in 1990 and is headquartered in Sunnyvale, California.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-12-04 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ALGN Align Technology, Inc

+10.72 (+2.10%)

USD40.29B 23.25 88.92
PODD Insulet Corporation

+3.34 (+1.31%)

USD16.85B 580.77 140.27
LVGO Livongo Health, Inc

N/A

USD14.20B N/A N/A
ABMD Abiomed, Inc

+5.77 (+2.16%)

USD12.06B 58.65 47.74
BRKR Bruker Corporation

+1.35 (+2.58%)

USD8.01B 51.69 25.34
TNDM Tandem Diabetes Care, Inc

-1.35 (-1.41%)

USD5.97B N/A N/A
IART Integra LifeSciences Holdings ..

+1.47 (+2.68%)

USD4.63B 83.21 22.22
SDC SmileDirectClub, Inc

-0.31 (-2.70%)

USD4.61B N/A N/A
WMGI Wright Medical Group N.V

N/A

USD3.90B N/A 50.67
AHCO AdaptHealth Corp

+0.68 (+1.98%)

USD3.07B -99,999.99 28.65

ETFs Containing ARAY

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Medical Devices)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 52.84% 75% C 80% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 52.84% 75% C 80% B-
Trailing 12 Months  
Capital Gain 49.65% 79% C+ 77% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 49.65% 79% C+ 77% C+
Trailing 5 Years  
Capital Gain -36.71% 42% F 21% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -36.71% 42% F 19% F
Average Annual (5 Year Horizon)  
Capital Gain -16.73% N/A N/A 13% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -16.73% N/A N/A 12% F
Risk Return Profile  
Volatility (Standard Deviation) 17.00% N/A N/A 76% C
Risk Adjusted Return -98.38% N/A N/A 4% F
Market Capitalization 0.37B 56% F 49% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Devices)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 27.00 50% F 38% F
Price/Book Ratio 5.82 43% F 24% F
Price / Cash Flow Ratio -251.64 100% A+ 98% A+
EV/EBITDA 12.56 69% D+ 59% F
Management Effectiveness  
Return on Equity 25.06% 95% A 94% A
Return on Invested Capital 4.62% 79% C+ 59% F
Return on Assets 3.00% 86% B 74% C
Debt to Equity Ratio 297.49% 13% F 6% F
Technical Ratios  
Short Ratio 5.81 38% F 27% F
Short Percent 5.68% 36% F 35% F
Beta 2.10 12% F 12% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector